rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PRTC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

      BOSTON, October 26, 2026--PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026

      Oct 26Yahoo FinancePRTC
      PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
      Oct 7Yahoo FinancePRTC
      PureTech Health gets Panmure Liberum ‘buy’ on value and cash returns
      Oct 7Yahoo FinancePRTC
      PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...

      PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.

      Sep 22Yahoo FinancePRTC
      PureTech Health H1 Earnings Call Highlights

      PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit

      Sep 22Yahoo FinancePRTC
      Earnings call transcript: PureTech Health highlights cash discipline in H1 2026
      Sep 22Investing.comPRTC
      PureTech’s LYT-200 receives FDA fast track for blood cancer
      Sep 21Investing.comPRTC
      PureTech Health to Report Half-Year 2026 Results on 22 September

      PureTech Health plc (LSE:PRTC) said it will publish its results for the six months ended 30 June 2026 on Tuesday, 22 September 2026. The company will hold a presentation and conference call at 9:00 a.

      Sep 4Yahoo FinancePRTC
      PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

      BOSTON, August 25, 2026--PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

      Aug 25Yahoo FinancePRTC

      This is the newest page. Registered accounts read further back.